Yu liva sɛf fat? Lɛ wi tɔk bɔt di Mɛtabolik Disfɔkshɔn-Asɔsiet Steatɔtik Liva Disease (MASLD) .

Yu dɔn ɛva tink se di ekstra wet we yu de kɛr ɔ wan sik lɛk dayabitis we yu gɛt kin afɛkt yu liva bak? Sɔntɛnde, wi kin bigin fɔ gɛda fat na wi liva we wi nɔ no. Dat na wan pan di kɔndishɔn dɛn we wi go tɔk bɔt tide, we dɛn kɔl MASLD. Nɔ wɔri, lɛ wi ɔndastand dis simpul wan.

Wetin na dis MASLD?

Fɔ tɔk am simpul wan, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) na wan sik we de kam pan yu liva we yu gɛt bɔku bɔku fat insay yu liva sɛl dɛn. Dɛn kin kɔl am bak steatotic (fatty) liver disease (SLD) . Fɔs dɛn bin de kɔl am NAFLD (Nonalcoholic Fatty Liver Disease), we min se fat kin gɛda na di liva fɔ rizin *nɔto* bikɔs ɔf rɔm. Bɔt naw dɛn dɔn chenj dis nem to MASLD, bikɔs dɛn dɔn si se i gɛt fɔ du wit sɔm abnɔmal tin dɛn we de apin na wi bɔdi in mɛtabolism.

Jɔs lɛk aw dɔti kin gɛda na wi os, we fat kin gɛda na di liva, as tɛm de go i kin mek pɔsin gɛt epataytis, we na inflamɛns na di liva. Dis sik na wan pan de sik wae de kam pan pɔrsin wae nɔr de mɛn na di wɔl. I kin mɔna pipul dɛn we fat ɛn we gɛt tayp 2 dayabitis. As dɛn tin ya de go ɔp, masta sabi pipul dɛn se pas 30% pan di pipul dɛn na di wɔl kin gɛt MASLD. If dɛn nɔ trit MASLD, i kin mek pɔsin gɛt mɔ siriɔs liva sik. So, if yu no dis sik kwik kwik wan ɛn trit yu, dat kin mek yu nɔr wɔs.

Wetin na di sayn dɛm fɔ MASLD?

Bɔrku tɛm, dis sik wae dɛn kɔl MASLD kin kam fɔ lɔng tɛm ɛn nɔr kin sho ɛni sayn na di fɔs stej. Dis min se de sik kin de insay yu bɔdi wae yu nɔr de fil ɛni difrɛns. Tink bɔt am as prɔblɛm we de gro wit sɛns.

Bɔt sɔm sayn dɛn kin bigin fɔ sho we dis sik rich wan stej we rili bad we dɛn kɔl MASH (Metabolic Dysfunction-Associated Steatohepatitis). MASH na we di fat kin gɛda na di liva ɛn bigin fɔ pwɛl di liva wit di inflamɛns. dis kin mek yu gεt kכndyushכn lεk liva fibrosis, we na di fכmeshכn fכ ska tisu, כ sirosis. If dis kin apin, yu kin gɛt sɔm kayn sik lɛk:

• Yu kin gɛt sɔm pen ɔ nɔ kin fil fayn na di ɔp rayt pat na yu bɛlɛ, usay yu liva de .
• Fɔ fil taya ɛn nɔ gɛt layf we yu nɔ go ebul fɔ imajin.
• Di it nɔ de te.
• Fɔ fil lɛk se yu bɛlɛ dɔn blo.
• Fɔ bi tin fɔ no rizin.
• yu skin εn di wayt dεm na yu yay de tכn yכlכ (lεk janda, dכkta dεn kin kכl dis skleral icterus bak ).

If yu gɛt wan ɔ mɔ pan dɛn sayn ya, i impɔtant fɔ go to dɔktɔ.

Wetin na di tin dɛn we kin mek pɔsin gɛt MASLD?

di men rizin fכ divεlכp MASLD na we sכm abn כmal tin dεm de apin na di mεtabolik prכ sεs na yu bכdi. dis mεtabolism na di prכsεs we di it we wi de it de kכnvכlt to enεji. If ɛni prɔblɛm de na dis prɔses, MASLD kin apin. Na sɔm pan di men tin dɛn we kin afɛkt dis:

• Dislipidemia: Dis na we di fat we de na yu blɔd, mɔ di lipid dɛn lɛk kɔlɔstrel, bɔku pas aw i fɔ bi.
• Fat: If yu Bɔdi Mas Indeks (BMI) na 30 ɔ pas dat, dɛn kin tek yu as pɔsin we fat. Pipul dɛn we gɛt bɔku bɔku fat, mɔ we de rawnd di bɛlɛ, kin gɛt mɔ risk fɔ gɛt MASLD.
• Insulin resistance: Insulin na ɔmon we de kɔntrol di lɛvɛl we di shuga (glucose) de na wi blɔd. Insulin resistance min se yu mɔsul, fat sɛl, ɛn liva sɛl nɔ de ansa fayn to insulin. Dis kin mek i nɔ izi fɔ kɔntrol di shuga we de na di blɔd.
• Tayp 2 dayabitis: Dis na sik bak we kin de fɔ lɔng tɛm. Wetin kin apin ya na dat di blɔd shuga kin bɔku ɔltɛm (haypa glycemia).

Apat frɔm dɛn tin ya, risach dɔn sho se sɔm chenj dɛn na di jɛnɛtiks kin mek bak di risk fɔ gɛt MASLD.

Wetin na di prɔblɛm dɛn we kin kam wit MASLD?

Wi dɔn tɔk bɔt aw sɔm pipul dɛm wae gɛt MASLD kin gɛt wan sik wae dɛn kɔl MASH. If dis MASH kɔndishɔn kam tranga, dɛn prɔblɛm ya kin apin:

• MASH wit liva fibrosis: Fibrosis na di fכmeshכn fכ ska tisu na di liva. Dis skata kin apin we di liva sɛl dɛn dɔn pwɛl ɛn tray fɔ mek dɛnsɛf fayn.
• Sirosis we gɛt fɔ du wit MASH: Sirosis na wan sik we di liva kin pwɛl bad bad wan ɛn i nɔ kin ebul fɔ wok igen. Dis na tin we rili siriɔs ɛn i kin mek pɔsin in layf de pan denja.
• Liva kansa (Hepatocellular carcinoma): Dis na wan kayn liva kansa we kin kam wit MASH.

MASLD nɔ kin jɔs mek dɛn gɛt dɛn prɔblɛm ya we gɛt fɔ du wit di liva, bɔt i kin mek yu gɛt ɔda siriɔs sik dɛn bak. Fɔ ɛgzampul:

• Kansa: Na kayn kansa lɛk bɔdi kansa ɛn kɔlorektal kansa.
• Di sik wae de kam wit di at ɛn di blɔd vesel dɛm: Sik dɛm wae gɛt fɔ du wit di at ɛn di blɔd vesel dɛm.
• Dayabitis: Pipul wae nɔr gɛt dayabitis naw kin gɛt nyu shuga.

Aw dɛn kin no se pɔsin gɛt MASLD?

Fɔ no fɔ tru if yu gɛt MASLD, dɔktɔ dɛn kin du bɔku blɔd tɛst ɛn imej tɛst. Sɔntɛnde, dɛn kin nid bak fɔ tek smɔl pat pan di liva fɔ tɛst (liva bayɔpsi).

Blɔd tɛst dɛn

Di dɔktɔ kin du bɔku blɔd tɛst dɛn, lɛk:

• A1C tɛst: Dis de mɛzhɔ yu avɛrej blɔd shuga lɛvɛl fɔ di pas tu to tri mɔnt.
• Kɔmplit Blɔd Kɔnt (CBC): Dis de chɛk di amɔnt ɛn di kwaliti dɛn we di difrɛn kayn sɛl dɛn we de na yu blɔd gɛt.
• Comprehensive Metabolic Panel (CMP): Dis de tεst di lεvεl dεm fכ lεk 14 tin dεm na yu bכdi, lεk protin dεm εn εlektrolayt dεm.
• Lipid panɛl: Dis na tɛst fɔ sik dɛn we de ambɔg di at ɛn di blɔd. I de mכsu di lεvεl dεm fכ di fεt pat dεm (kכlestכl, triglisεrayd) na yu bכdi.
• di liva fכnshכn tεst dεm: dεn bכdi tεst dεm ya de mכsu difrεn tin dεm (εnzym, protin) we di liva de mek fכ gi wan aidia fכ di hεlth fכ di liva.

Test dɛn fɔ tek imej

Yu dɔktɔ kin du skan lɛk dis fɔ chɛk fɔ si if yu gɛt sayn dɛn fɔ MASLD na yu liva:

• FibroScan®: Dis skan kin gi yu aidia bɔt di fat we de na yu liva ɛn di kayn we aw di fibrosis de.
• Magnεtik Rεsכnans εlastografi εn Protכn Dεnsiti Fεt Frakshכn (MRE-PDFF): Dis na spεshal kayn skan bak. i kin mכsu di pasεnshכn fεt na di liva εn di digri we di fibrosis de.

Bayopsi we dɛn kin du

Na smɔl tɛm nɔmɔ, if yu dɔktɔ sɔprayz se na ɔda tin pas MASLD, ɔ if dɛn nid mɔ infɔmeshɔn afta dɛn dɔn du tɛst lɛk fibroscan, dɛn kin tek wan smɔl tisu frɔm yu liva (liva bayɔpsi) ɛn chɛk am ɔnda maykroskɔp.

Aw dɛn kin trit MASLD?

We dɛn de trit MASLD, di fɔs tin we dɛn fɔ pe atɛnshɔn pan na fɔ lɛf fɔ it bɔku bɔku it dɛn . Apat frɔm dat, dɛn kin trit di ɔndalayn kɔndishɔn dɛn we mek MASLD, lɛk dayabitis, ay kɔlɔstrel, ɛn ay blɔd prɛshɔn, bak.

Infakt, we yu lɛf fɔ it bɔku bɔku it, dat kin mek yu liva gɛt big difrɛns. If yu ridyus di fat we pasmak na di liva, i kin ɛp fɔ kɔntrol di inflamɛns we kin mek yu gɛt tin dɛn lɛk sirosis. Yu dɔktɔ kin tɛl yu fɔ tek spɛshal it plan, lɛk di it we dɛn kin it na Mɛditarenian ɔ di it we dɛn kɔl DASH. Wi go tɔk bɔt dɛn it ya insay wan ɔda atikul.

If yu du ɛksɛsayz fɔ at le 30 minit insay di de, tri dez insay di wik, dat kin ɛp yu fɔ lɛf fɔ it bɔku bɔku it dɛn. Yu dɔktɔ kin tɛl yu fɔ lɔs 10% ɔ mɔ pan yu ɔl bɔdi wet. Bɔt ivin if yu lɔs 3% to 5% pan yu bɔdi wet kin mek big difrɛns .

Mɛrɛsin fɔ lɛ pɔsin nɔ gɛt bɔku bɔku bɔdi

If yu gɛt dayabitis ɛn/ɔ yu fat, yu dɔktɔ kin gi yu mɛrɛsin fɔ mek yu nɔ gɛt bɔku bɔku bɔdi, lɛk GLP-1 agonists. Dɛn mɛrɛsin ya kin mek yu blɔd shuga go dɔŋ ɛn ɛp yu fɔ lɛf fɔ it bɔku bɔku it dɛn. Sɔm ɛgzampul dɛn na:

• Semaglutayd (Sɛmaglutayd - Ozempic® ɔ Wegovy®) .
• Liraglutayd (Liraglutayd - Viktoza® ɔ Saksɛnda®) .
• Tirzepatid (Mɔnjaro® ɔ Zɛpbɔund®) .

Bariatric ɔpreshɔn we dɛn kin du

Sɔntɛnde, yu dɔktɔ kin tɔk to yu bak bɔt bariatric ɔpreshɔn. If dɛn no se yu gɛt MASLD bifo sirosis bigin, dis ɔpreshɔn fɔ lɔs yu wet kin rivɛns di kɔndishɔn.

Yu tink se dɛn kin chenj di tin we de apin na di MASLD?

Yɛs, i kin bi! Bɔt i dipen pan di tin we de apin to yu. Jɛnɛral wan, if yu nɔ gɛt sirosis we gɛt fɔ du wit MASH, tritmɛnt kin rivɛns MASLD.

I impɔtant fɔ no dis sik kwik kwik wan . Dis kin ɛp fɔ kɔntrol di damej we di liva gɛt bifo i tu siriɔs. If yu lɔs yu wet ɛn chenj yu layf, dat kin ɛp fɔ rivɛns di damej we MASLD dɔn mek to di liva. Bɔt dis kin dipen pan yu ɔl wɛlbɔdi biznɛs. So, aks yu dɔktɔ if we yu lɛf fɔ it bɔku bɔku it, dat kin mek yu nɔ gɛt prɔblɛm.

Yu tink se dɛn kin mek dɛn nɔ gɛt MASLD?

Bɔrku tɛm dis sik kin afɛkt pipul dɛm wae fat pasmak ɛn gɛt tayp 2 dayabitis. Sɔntɛm i nɔ go pɔsibul fɔ mek dɛn nɔ gɛt dɛn sik ya kpatakpata. Bɔt fɔ no kwik kwik wan ɛn chenj dɛn layf kin ɛp fɔ mek dɛn nɔ gɛt ɔ kɔntrol di divɛlɔpmɛnt fɔ MASLD.

If yu fat ɔ yu gɛt tayp 2 dayabitis, yu dɔktɔ kin tɛl yu fɔ du blɔd tɛst ɛn skan fɔ chɛk fɔ si if yu gɛt sayn dɛn fɔ dis sik. If dɛn kech yu kwik, yu kin chenj yu layf fɔ ridyus di prɔblɛm we yu gɛt.

Aw lɔŋ yu kin liv wit MASLD?

Risach dɔn sho se if yu gɛt MASLD, i kin afɛkt yu layf. Fɔ ɛgzampul, wan stɔdi dɔn sho se pipul dɛn we gɛt MASLD kin liv fɔ lɛk 2.8 ia so pas di wan dɛn we nɔ gɛt dis sik.

Bɔt bɔku tin kin afɛkt aw lɔng yu go liv wit MASLD. Di tin we de apin to yu kin difrɛn frɔm ɔda pipul dɛn. So, yu dɔktɔ na di bɛst tin fɔ no bɔt wetin yu go ɛkspɛkt.

Aw a kin kia fɔ misɛf?

If yu gɛt MASLD, di bɛst we fɔ tek kia ɔf yusɛf na fɔ wok wit yu dɔktɔ dɛn fɔ kɔntrol di tin dɛn we mek yu gɛt MASLD, lɛk fɔ gɛt bɔku bɔku bɔdi, fɔ fat pasmak, ɛn fɔ gɛt tayp 2 dayabitis. If yu lɔs yu wet ɛn kɔntinyu fɔ du tin, dat kin ɛp fɔ ridyus, ɛn sɔntɛm fɔ rivɛns, di liva we de pwɛl.Na sɔm ɔda advays dɛn ya:

• Yu fɔ no bɔt yu ɔl wɛlbɔdi biznɛs. MASLD kin mek yu gɛt dayabitis, at sik, ɛn sɔm kayn kansa. So, aks yu famili dɔktɔ bɔt us tɛst yu kin du fɔ ridyus yu risk.
• Divɛlɔp abit dɛn we fayn fɔ yu liva. Lɛf fɔ smok ɛn drink rɔm. Smok ɛn rɔm kin mek yu liva strɛs mɔ. Aks yu dɔktɔ bak bɔt fɔ gɛt vaysin agens epataytis A ɛn epataytis B.
• Nɔ giv ɔp, kɔntinyu fɔ tray.

Fɔ lɛ yu nɔ gɛt bɔku bɔku bɔdi kin tek tɛm. Sɔntɛm yu nɔ go si big difrɛns wantɛm wantɛm, bɔt yu go si di tin dɛn we go apin smɔl smɔl. Dɔn bak, fɔ ɛksesaiz ɔltɛm na sɔntin we yu fɔ du. If yu fil taya ɔr bɔrku pan dis waka, tɔk to yu dɔktɔ bɔt am.

Ustɛm a fɔ go to dɔktɔ?

If yu notis ɛni chenj na yu bɔdi, lɛk fɔ fil taya pas aw yu kin fil ɔ fɔ gɛt pen na di ɔp rayt say na yu bɛlɛ, mek shɔ se yu go to yu dɔktɔ . dis chenj dεm kin sho se yu gεt siriכs kes fכ MASH, we na wan kכndyushכn fכ fεt liva sik we kin go bifo to mכr siriכs kכndyushכn lεk sirosis εn εpatosεlula kansa.

Yu tink se fɔ drink rɔm kin mek yu gɛt MASLD?

Nɔ, fɔ drink rɔm nɔ kin mek pɔsin gɛt MASLD dairekt wan. As wi bin dɔn tɔk, dɛn bin de kɔl dis fɔs nɔ-alcoholic fatty liver disease (NAFLD). Dis min se dis sik kin kam ivin if yu nɔr de drink bɔrku rɔm.

Bɔt, di tin we impɔtant pas ɔl na dat if pɔsin we gɛt MASLD drink rɔm, dɛn kin gɛt bɔku bɔku risk fɔ gɛt sirosis pas di avɛrej pɔsin. Na dat mek dɔktɔ dɛn kin advays pipul dɛn we gɛt MASLD fɔ avɔyd fɔ drink rɔm ɔltogɛda.

Fɔ dɔn, tin dɛn we wi fɔ mɛmba

If yu de du blɔd tɛst we yu de du yu fizik ɛvri ia sho se yu gɛt prɔblɛm wit yu liva, dɛn kin du ɔda tɛst fɔ no se yu gɛt MASLD. Dis liva sik kin mek yu gɛt mɔ siriɔs prɔblɛm if yu nɔr de mɛn am fayn.

Bɔt di gud nyus na dat, chenj na yu layf, lɛk fɔ lɛf fɔ it bɔku bɔku it ɛn fɔ de du tin, kin ɛp fɔ mek MASLD nɔ wɔs. Dɛn kin ivin rivɛns di damej we yu liva dɔn pwɛl. Bɔt fɔ lɔs yu wet ɛn fɔ bi aktif nɔto sɔntin we yu kin du wan nɛt. I kin tek tɛm ɛn gi in layf to Jiova. Sɔm dez, yu kin fil lɛk se yu de taya wit dɛn tin ya. Yu wɛl bɔdi tim ɔndastand de chalenj fɔ tray tin dɛm wae nɔr kin woke kwik kwik wan. So, nɔ ɛva shem fɔ aks fɔ ɛp ɛn sɔpɔt. Yu liva valyu to yu, ɛn na yu fɔ kia fɔ am!

` Liva fat, fat liva, dayabitis, fat, sirosis, liva wɛlbɔdi